News and Events Joni Henderson 3/29/23 Joni Henderson 3/29/23 C₂N’s PrecivityAD® Blood Test, Which Identifies Amyloid Pathology as an Aid to Alzheimer’s Disease Diagnosis, Further Demonstrates Its High Accuracy in Newly Published Research Read More Joni Henderson 2/16/23 Joni Henderson 2/16/23 C₂N Diagnostics Announces Follow-on Investment from GHR Foundation as It Builds on Success in Novel Diagnostics to Aid in Alzheimer’s Disease Fight Read More Guest User 12/8/22 Guest User 12/8/22 C₂N Diagnostics’ PrecivityAD® and PrecivityAD2™ Blood Tests at CTAD 2022 Highlight the Potential and Use of Blood Biomarkers in the Diagnosis of Alzheimer’s Disease Read More Guest User 11/29/22 Guest User 11/29/22 C₂N Diagnostics Introduces the PrecivityAD2™ Blood Test Read More Guest User 11/17/22 Guest User 11/17/22 International Researchers Poised to Learn New Insights About C₂N Diagnostics’Blood Test Innovations at Clinical Trials on Alzheimer’s Disease Conference Read More Guest User 10/21/22 Guest User 10/21/22 C₂N Diagnostics Marks Two Years of PrecivityAD® Blood Test Accomplishments Read More Guest User 9/21/22 Guest User 9/21/22 C₂N Diagnostics Partners with Grupo Fleury to Bring Pioneering Blood Tests to Brazil for Advancing Brain Health Read More Guest User 9/14/22 Guest User 9/14/22 Independent Research Finds Underlying Method for C₂N’s p-Tau217 RatioBlood Test Outperforms Other Tau Blood Tests Used for Alzheimer’s Diagnoses Read More Guest User 8/30/22 Guest User 8/30/22 C₂N Diagnostics and Healius Ltd Announce Partnership to Bring PrecivityAD™ and Related Brain Health Biomarkers to Patients in Australia Read More Guest User 8/23/22 Guest User 8/23/22 C₂N and Eisai Collaborate to Build Awareness and Real-World Evidence for Blood-Based Assays for Cognitive Impairment in Clinical Practice Outside of Clinical Trial Settings Read More Guest User 7/31/22 Guest User 7/31/22 C₂N Data Release for New Blood Test Combining p-tau217 Ratio with Amyloid beta 42/40 Read More Guest User 5/18/22 Guest User 5/18/22 C₂N Diagnostics Introduces P-tau Multi-Analyte Assay for Research Use Only to Advance Alzheimer’s Disease and Brain Health Field Read More Tim West 4/21/22 Tim West 4/21/22 JAMA Network Open Publishes Analysis of Results of Two Independent Studies Demonstrating the High Diagnostic Performance of the PrecivityAD™ Blood Test for Alzheimer’s Disease Read More Guest User 2/22/22 Guest User 2/22/22 C₂N Achieves ISO 13485:2016 Certification Latest Development for Leader in Brain Health Sector Read More Guest User 1/3/22 Guest User 1/3/22 C₂N Begins New Year with CAP Accreditation Award, the Highest Standard in Laboratory Practices Read More Tim West 11/12/21 Tim West 11/12/21 Major Research Findings Highlight Effectiveness of the PrecivityAD™ Blood Test That Clinicians Use to Aid in Alzheimer’s Disease Diagnosis Read More Tim West 9/21/21 Tim West 9/21/21 C₂N Opens State-of-the-Art CLIA Lab in St. Louis as Alzheimer’s Disease Blood Diagnostic Test Bests Others in Independent Comparison Studies Published in JAMA Neurology Read More Joni Henderson 7/29/21 Joni Henderson 7/29/21 Two Research Studies Bolster Method That C2N’s PrecivityAD™ Blood Test Uses to Aid Clinicians in Alzheimer’s Disease Diagnoses Read More Joni Henderson 7/21/21 Joni Henderson 7/21/21 Blood tests could help screen anticipated flood of patients seeking new Alzheimer’s drug Read More Joni Henderson 5/27/21 Joni Henderson 5/27/21 Peer-Reviewed Journal Publishes Analytical Validation Results for thePrecivityAD™ Blood Test, Which Can Help Clinicians Detect Alzheimer’s Disease Read More Newer Posts Older Posts Subscribe to our newsletter. Sign up with your email address to receive news and updates. First Name Last Name Email Address Sign Up Thank you!
Joni Henderson 3/29/23 Joni Henderson 3/29/23 C₂N’s PrecivityAD® Blood Test, Which Identifies Amyloid Pathology as an Aid to Alzheimer’s Disease Diagnosis, Further Demonstrates Its High Accuracy in Newly Published Research Read More
Joni Henderson 2/16/23 Joni Henderson 2/16/23 C₂N Diagnostics Announces Follow-on Investment from GHR Foundation as It Builds on Success in Novel Diagnostics to Aid in Alzheimer’s Disease Fight Read More
Guest User 12/8/22 Guest User 12/8/22 C₂N Diagnostics’ PrecivityAD® and PrecivityAD2™ Blood Tests at CTAD 2022 Highlight the Potential and Use of Blood Biomarkers in the Diagnosis of Alzheimer’s Disease Read More
Guest User 11/29/22 Guest User 11/29/22 C₂N Diagnostics Introduces the PrecivityAD2™ Blood Test Read More
Guest User 11/17/22 Guest User 11/17/22 International Researchers Poised to Learn New Insights About C₂N Diagnostics’Blood Test Innovations at Clinical Trials on Alzheimer’s Disease Conference Read More
Guest User 10/21/22 Guest User 10/21/22 C₂N Diagnostics Marks Two Years of PrecivityAD® Blood Test Accomplishments Read More
Guest User 9/21/22 Guest User 9/21/22 C₂N Diagnostics Partners with Grupo Fleury to Bring Pioneering Blood Tests to Brazil for Advancing Brain Health Read More
Guest User 9/14/22 Guest User 9/14/22 Independent Research Finds Underlying Method for C₂N’s p-Tau217 RatioBlood Test Outperforms Other Tau Blood Tests Used for Alzheimer’s Diagnoses Read More
Guest User 8/30/22 Guest User 8/30/22 C₂N Diagnostics and Healius Ltd Announce Partnership to Bring PrecivityAD™ and Related Brain Health Biomarkers to Patients in Australia Read More
Guest User 8/23/22 Guest User 8/23/22 C₂N and Eisai Collaborate to Build Awareness and Real-World Evidence for Blood-Based Assays for Cognitive Impairment in Clinical Practice Outside of Clinical Trial Settings Read More
Guest User 7/31/22 Guest User 7/31/22 C₂N Data Release for New Blood Test Combining p-tau217 Ratio with Amyloid beta 42/40 Read More
Guest User 5/18/22 Guest User 5/18/22 C₂N Diagnostics Introduces P-tau Multi-Analyte Assay for Research Use Only to Advance Alzheimer’s Disease and Brain Health Field Read More
Tim West 4/21/22 Tim West 4/21/22 JAMA Network Open Publishes Analysis of Results of Two Independent Studies Demonstrating the High Diagnostic Performance of the PrecivityAD™ Blood Test for Alzheimer’s Disease Read More
Guest User 2/22/22 Guest User 2/22/22 C₂N Achieves ISO 13485:2016 Certification Latest Development for Leader in Brain Health Sector Read More
Guest User 1/3/22 Guest User 1/3/22 C₂N Begins New Year with CAP Accreditation Award, the Highest Standard in Laboratory Practices Read More
Tim West 11/12/21 Tim West 11/12/21 Major Research Findings Highlight Effectiveness of the PrecivityAD™ Blood Test That Clinicians Use to Aid in Alzheimer’s Disease Diagnosis Read More
Tim West 9/21/21 Tim West 9/21/21 C₂N Opens State-of-the-Art CLIA Lab in St. Louis as Alzheimer’s Disease Blood Diagnostic Test Bests Others in Independent Comparison Studies Published in JAMA Neurology Read More
Joni Henderson 7/29/21 Joni Henderson 7/29/21 Two Research Studies Bolster Method That C2N’s PrecivityAD™ Blood Test Uses to Aid Clinicians in Alzheimer’s Disease Diagnoses Read More
Joni Henderson 7/21/21 Joni Henderson 7/21/21 Blood tests could help screen anticipated flood of patients seeking new Alzheimer’s drug Read More
Joni Henderson 5/27/21 Joni Henderson 5/27/21 Peer-Reviewed Journal Publishes Analytical Validation Results for thePrecivityAD™ Blood Test, Which Can Help Clinicians Detect Alzheimer’s Disease Read More
